Nader Marta, Guilherme http://orcid.org/0000-0001-7864-3637
Isaacsson Velho, Pedro
Bonadio, Renata R. C.
Nardo, Mirella
Faraj, Sheila F.
de Azevedo Souza, Manoel Carlos L.
Muniz, David Q. B.
Bastos, Diogo Assed
Dzik, Carlos
Article History
Received: 29 February 2020
Accepted: 10 June 2020
First Online: 24 June 2020
Compliance with Ethical Standards
:
: Guilherme Nader Marta has received travel/accommodations grants from Bayer Schering Pharma and Roche.Pedro Isaacsson Velho has received research funding to his institution from Bristol Myers-Squibb and honoraria/consulting fee from Roche, AstraZeneca Bristol Myers-Squibb and Pfizer.Renata R. C. Colombo Bonadio has received travel grants from Roche.Mirella Nardo has no conflict of interest to declare.Sheila F. Faraj has no conflict of interest to declare.Manoel Carlos L. de Azevedo Souza has received speakers bureau’s grants from Novartis, MSD, Bristol Myers-Squibb and Amgen and has received travel/accommodations grants from Astellas and Zodiac.David Q. B. Muniz: has received research funding to his institution from Pfizer, travel/accommodations grants from Janssen and has received speakers bureau’s grants from Pfizer and Janssen.Diogo Assed Bastos has received research funding to his institution from Janssen, Astellas, Pfizer and honoraria/consulting fee from Roche, Janssen, MSD.Carlos Dzik has received consulting or advisory grants from Janssen-Cilag, Ipsen, Novartis; speakers bureau’s grants Janssen Oncology and travel/accommodations from Astellas Pharma, Janssen Oncology.
: This study was approved by the institutional research center (NP 716/14).
: In view of the retrospective nature of this study, waiver of consent was requested.
: not applicable.